Epidermal growth factor

Xem 1-20 trên 422 kết quả Epidermal growth factor

Association of hormone receptors and human epidermal growth factor receptor-2/ neu expressions with clinicopathologic factors of breast carcinoma: A cross-sectional study in a tertiary care hospital, Kabul, Afghanistan

Breast cancer (BC) is one of the major causes of death worldwide. It is the most common cause of death before the age of 70 years. The incidence and mortality of BC are rapidly increasing, posing great challenges to the health system and economy of every nation.

11p vishanshan 27-06-2024 1 1 Download

The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD

The clinical value and impact in patients with EGFR mutation on survival outcomes is further needed to be elucidated to decide whether the application of EGFR-TKIs was appropriate in early lung adenocarcinoma (LUAD) stage appearing as subsolid nodules.

9p vishanshan 27-06-2024 3 1 Download

Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases

Predicting short-term efficacy and intracranial progression-free survival (iPFS) in epidermal growth factor receptor gene mutated (EGFR-mutated) lung adenocarcinoma patients with brain metastases who receive third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy was of great significance for individualized treatment.

15p vishanshan 27-06-2024 1 1 Download
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: A real-world study

Both first and second-generation EGFR-TKIs are recommended in advanced NSCLC with common EGFR mutations. However, there are few data on the difference in efficacy of EGFR-TKIs based on the type of EGFR mutation and agents.

10p vishanshan 27-06-2024 1 1 Download
Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer

Evaluation of human epidermal growth factor receptor 2 (HER2) overexpression caused by erbb2 receptor tyrosine kinase 2 (ERBB2) amplification (AMP) by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is essential for treating unresectable metastatic gastric cancer (GC).

13p vikoch 27-06-2024 1 1 Download
New evidence: Metformin unsuitable as routine adjuvant for breast cancer: A drugtarget mendelian randomization analysis

The potential efficacy of metformin in breast cancer (BC) has been hotly discussed but never conclusive. This genetics-based study aimed to evaluate the relationships between metformin targets and BC risk.

11p vikoch 27-06-2024 1 1 Download
Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: A case study of Osimertinib versus pemetrexed-platinum

The partitioned survival model (PSM) and the state transition model (STM) are widely used in costeffectiveness analyses of anticancer drugs. Using different modeling approaches with or without consideration of brain metastasis, we compared the quality-adjusted life-year (QALY) estimates of Osimertinib and pemetrexedplatinum in advanced non-small cell lung cancer with epidermal growth factor receptor mutations.

11p vikoch 27-06-2024 1 1 Download
Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2- positive gastric or gastro-oesophageal adenocarcinoma: A meta-analysis of randomized clinical trials

The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)- positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJ) is not yet fully elucidated.

11p vikoch 27-06-2024 1 1 Download
Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients

The superior efficacy of concurrent thoracic radiotherapy (TRT) and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been proven in locally advanced and advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations.

10p vikoch 27-06-2024 1 1 Download
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: A real-world observational study

The irreversible epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) afatinib and dac‑ omitinib are approved for first-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and dacomitinib in this setting.

11p vikoch 27-06-2024 1 1 Download
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced nonsmall cell lung cancer in Vietnam

This study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting in Vietnam. Methods This retrospective study was conducted across nine hospitals in Vietnam. Advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients who received afatinib as first-line therapy between April 2018 and June 2022 were included, and patient medical records were reviewed.

10p vikoch 27-06-2024 1 1 Download
Clinical factors predecting T790M mutation in non-small cell lung cancer progressed after-first - and second-generation TKI treatment

We aimed to identify the T790M mutation rate and clinical factors predicting the occurrence of acquired T790M mutations in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after first- and secondgeneration tyrosine kinase inhibitor (TKI) treatment.

9p vicarlos 16-05-2024 1 0 Download
In silico screening of alkaloids as potential inhibitors of HER2 protein for breast cancer treatment

his study focused on finding alkaloid compounds collected from Chemfaces database that inhibit HER2 enzyme employing computational methods such as molecular docking and ADMET prediction. Out of 118 phytochemicals docked to the ATP binding site of the HER2 kinase domain, 10 alkaloid compounds exhibited higher binding affinity than the reference inhibitor and satisfied the Lipinski’s rule of five. All compounds have good pharmacokinetic properties.

10p dianmotminh02 03-05-2024 3 2 Download
Molecular docking and molecular dynamics approach to identify EGFR and HER2 receptors inhibitory effect of compounds in Zanthoxylum simulans Hance

Epidermal growthfactor receptor(EGFR) and human epithelium receptor-2(HER2) are members of the epidermal growth factor receptor (EGFR/ErbB) family implicated in the development of many types of carcinoma. Zanthoxylum simulans Hance has the effect of inhibiting growth and causing the death of many types of cancer cells. In this study, the molecular docking method and molecular dynamics simulations were used to evaluate the inhibition abilities of EGFR and HER2 receptors of 120 compounds in Zanthoxylum simulans Hance.

12p dianmotminh02 03-05-2024 3 2 Download
Ebook Breast cancer chemosensitivity

Ebook "Breast cancer chemosensitivity" include in-depth discussions on multidrug resistance by P-glycoprotein and the multidrug resistance protein family, resistance to therapeutic agent-induced apoptosis, cell cycle deregulation, deregulation of DNA repair, loss of tumor suppressor genes, integrin-mediated adhesion, insulin-like growth factors, epidermal growth factor, and ErbB2 in modulating breast cancer response to systemic therapy, especially, certain chemotherapeutic agents.

187p tracanhphuonghoa1007 22-04-2024 3 1 Download
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested in vivo selection of anti-EGFR SR tumors in CRC patient-derived xenograft (PDX) models as a strategy for a molecular dissection of SR mechanisms.

25p vibransone 28-03-2024 2 2 Download
A preliminary study to establish the transfected CHO cell lines which highly express Trastuzumab - A biosimilar product of Herceptin

Human epidermal growth factor receptor 2 (HER2) has been identified as a molecular target for breast cancer therapy, such as Trastuzumab (Herceptin®). This has been shown to improve patient survival substantially.

10p vibego 02-02-2024 0 0 Download
Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: A case report

The discovery of epidermal growth factor receptor oncogenic driver mutations has changed the therapeutic landscape of advanced non-small cell lung cancer in the past decade. Since the introduction of next generation sequencing, uncommon epidermal growth factor receptor mutations are more frequently discovered.

5p vilazada 31-01-2024 4 2 Download
Pure tubular carcinoma of the breast: A case series

Pure tubular breast carcinoma is a rare and well-differentiated tumor with high survival and low local recurrence rate. Our study aims to determine the clinical, radiological, appropriate management, and prognosis of this carcinoma.

5p vitiki 30-01-2024 6 2 Download
Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer

Gastric cancer is the most fifth common tumor worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis and clinical characteristics in gastric cancer. Nevertheless, the biology of HER2-low expression has not reported in gastric cancer.

6p vileonardodavinci 23-12-2023 6 3 Download